Latigo Biotherapeutics, Inc. Common Stock (LTGO) - Total Liabilities
Based on the latest financial reports, Latigo Biotherapeutics, Inc. Common Stock (LTGO) has total liabilities worth $303.16 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. For the complete balance sheet picture, see Latigo Biotherapeutics, Inc. Common Stoc balance sheet assets.
Latigo Biotherapeutics, Inc. Common Stock - Total Liabilities Trend (2024–2025)
This chart illustrates how Latigo Biotherapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See LTGO net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Latigo Biotherapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Latigo Biotherapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xinjiang Communications Construction Group Co Ltd Class A
SHE:002941
|
China | CN¥13.91 Billion |
|
ZYNP Corp
SHE:002448
|
China | CN¥2.39 Billion |
|
Sichuan Haite High-tech Co Ltd
SHE:002023
|
China | CN¥2.26 Billion |
|
Leshan Giantstar Farming & Husbandry Corp Ltd
SHG:603477
|
China | CN¥6.45 Billion |
|
BioPharma Credit PLC
LSE:BPCR
|
UK | $7.49 Million |
|
Goldman Sachs BDC Inc
NYSE:GSBD
|
USA | $1.93 Billion |
|
Sitronix Technology Corp
TW:8016
|
Taiwan | NT$7.93 Billion |
|
Prospect Capital Corporation
NASDAQ:PSEC
|
USA | $2.01 Billion |
Liability Composition Analysis (2024–2025)
This chart breaks down Latigo Biotherapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 5.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Latigo Biotherapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Latigo Biotherapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Latigo Biotherapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $307.19 Million | +101.48% |
| 2024-12-31 | $152.46 Million | -- |
About Latigo Biotherapeutics, Inc. Common Stock
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting … Read more